** U.S.-listed shares of Australia-based drug developer
Immuron more than double to $4.52 in premarket trading
** IMRN says its experimental drug, Travelan, was shown to
be significantly effective in preventing moderate to severe
diarrhea caused by enterotoxigenic Escherichia coli (ETEC)
infection, according to interim data from a mid-stage study
** ETEC infection is caused by ingestion of contaminated
food and water and is the most common illness reported by
travelers visiting developing countries and among U.S. troops
deployed overseas
** A single dose of the Travelan showed 36.4% protective
efficacy against ETEC-induced moderate to severe diarrhea
compared to placebo - Co
** Co expects to report final data in H2 2024
** Says IMRN is exploring non-dilutive funding opportunities
for late-stage studies of the drug
** Up to last close, U.S.-listed stock down 19% in the last
12 months
(Reporting by Mariam Sunny in Bengaluru)
((Mariam.ESunny@thomsonreuters.com;))